Literature DB >> 26431837

[Update on extracorporeal photopheresis].

U Just1, R Knobler2.   

Abstract

Extracorporeal photopheresis (ECP) is a treatment approach that combines leukapheresis with photochemotherapy and is derived from PUVA; with this procedure, nucleated cells such as lymphocytes and monocytes are extracorporeally irradiated with UVA light after photosensitization. ECP is an effective treatment modality with few side effects that in recent years has been expanded to treat a range of indications. It has been proven effective in the treatment of cutaneous T cell lymphoma and is being increasing used in other lymphocyte-mediated, autoimmune and inflammatory diseases that are associated with proliferation of autoreactive T cells.

Entities:  

Keywords:  Indication; Leukapheresis; Photochemotherapy; T cells; Therapy

Mesh：

Substances：

Year:  2015        PMID： 26431837     DOI： 10.1007/s00105-015-3702-1

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  29 in total

1.  Short German guidelines: cutaneous lymphomas.

Authors:  Rudolf Stadler; Chalid Assaf; Claus-Detlev Klemke; Dorothee Nashan; Michael Weichenthal; Reinhard Dummer; Wolfram Sterry
Journal:  J Dtsch Dermatol Ges       Date:  2008-05       Impact factor: 5.584

2.  Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution.

Authors:  E Bisaccia; J Gonzalez; M Palangio; J Schwartz; A S Klainer
Journal:  J Am Acad Dermatol       Date:  2000-08       Impact factor: 11.527

3.  Extracorporeal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma.

Authors:  M Di Renzo; P Rubegni; G De Aloe; L Paulesu; A L Pasqui; L Andreassi; A Auteri; M Fimiani
Journal:  Immunology       Date:  1997-09       Impact factor: 7.397

4.  Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial.

Authors:  A H Rook; B Freundlich; B V Jegasothy; M I Perez; W G Barr; S A Jimenez; R L Rietschel; B Wintroub; M B Kahaleh; J Varga
Journal:  Arch Dermatol       Date:  1992-03

5.  Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells.

Authors:  Akira Maeda; Agatha Schwarz; Kerstin Kernebeck; Nicole Gross; Yoshinori Aragane; David Peritt; Thomas Schwarz
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

Review 6.  Transimmunization, a novel approach for tumor immunotherapy.

Authors:  Carole L Berger; Douglas Hanlon; Daniel Kanada; Michael Girardi; Richard L Edelson
Journal:  Transfus Apher Sci       Date:  2002-06       Impact factor: 1.764

7.  FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.

Authors:  Julia B Heid; Angelika Schmidt; Nina Oberle; Sergij Goerdt; Peter H Krammer; Elisabeth Suri-Payer; Claus-Detlev Klemke
Journal:  J Invest Dermatol       Date:  2009-07-23       Impact factor: 8.551

8.  Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results.

Authors:  R Edelson; C Berger; F Gasparro; B Jegasothy; P Heald; B Wintroub; E Vonderheid; R Knobler; K Wolff; G Plewig
Journal:  N Engl J Med       Date:  1987-02-05       Impact factor: 91.245

9.  Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells.

Authors:  Iolanda Di Biaso; Lucia Di Maio; Cristina Bugarin; Giuseppe Gaipa; Erica Dander; Adriana Balduzzi; Matteo Parma; Giovanna D'Amico; Paolo Perseghin; Andrea Biondi; Ettore Biagi
Journal:  Transplantation       Date:  2009-05-15       Impact factor: 4.939

Review 10.  Photopheresis: a new therapeutic concept.

Authors:  R L Edelson
Journal:  Yale J Biol Med       Date:  1989 Nov-Dec
View more
  1 in total

Review 1.  [Treatment of mycosis fungoides and Sézary syndrome].

Authors:  J P Nicolay; C Assaf
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.